Borrelia burgdorferi peptidoglycan as a diagnostic and target for therapeutic intervention of Lyme disease-related pathologies
AssigneeVirginia Tech Intellectual Properties, Inc.
InventorsBrandon L. Jutras, Christine Jacobs-Wagner
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a method of diagnosing Lyme disease in a subject comprising measuring the level of B. burgdorferi peptidoglycan or the level of an antibody that specifically binds to B. burgdorferi peptidoglycan (“anti-peptidoglycan agent”). The present disclosure also relates to a method of treating a Lyme disease in a subject in need thereof comprising administering to the subject an antagonist against B. burgdorferi peptidoglycan (e.g., an anti-peptidoglycan antibody or a peptidoglycan-specific hydrolase). Antagonists (e.g., anti-peptidoglycan antibodies) suitable for the present methods are also disclosed.
Claims9
A method of diagnosing Lyme disease arthritis in a subject in need thereof comprising:
- (i) contacting, with a synovial fluid sample of the subject, an innate immunity protein that binds to Borrelia burgdorferi peptidoglycan, wherein the innate immunity protein is NOD2;
- (ii) detecting binding between NOD2 and peptidoglycan;
- and
- (iii) measuring the level of peptidoglycan in the sample based at least upon the amount of binding detected between NOD2 and peptidoglycan.
Dependencies are inferred from the claim text.